Leukemia News

Numerous academic medical centers around the world have demonstrated the ability to develop and produce safe and effective chimeric antigen receptor T-cell therapies.

Racial disparities in cancer clinical trial enrollment have existed for decades, with Black, Hispanic and other underserved populations prevented from accessing the same cutting-edge treatments as their white counterparts.

A collaborative team of cancer experts from leading academic institutions and organizations has released recommendations for optimal protection against COVID-19 among individuals with blood cancer.

Cierra Aber is a helper.

American Association for Cancer Research urged the CDC to expand availability of COVID-19 booster vaccinations to caregivers and other individuals who share a home with patients with cancer.

The FDA granted orphan drug designation to LAVA-051 for the treatment of chronic lymphocytic leukemia.

More than half of patients who received a single dose of CTX110 for relapsed or refractory large B-cell lymphoma responded to therapy, according to topline data released by the agent’s manufacturer.

Patients with lymphoid malignancies who received anti-CD20 therapy within the previous year did not demonstrate antibody responses to the messenger RNA COVID-19 vaccines, according to study results published in Blood Advances.

In this video, Farhad Ravandi, MD, spoke with Healio about the importance of measurable residual disease assessment in AML, which was discussed at the Society of Hematologic Oncology Annual Meeting.

In this video, Healio spoke with Farhad Ravandi, MD, about the promise of maintenance therapy in AML, which was discussed at the Society of Hematologic Oncology Annual Meeting.